CL
CLCS.US Cell Source Inc
- Market cap
- USD 29.9M
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is CLCS.US undervalued?
Graham numberThe Graham number of Cell Source Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Cell Source Inc fundamental analysis
No fundamental analysis for Cell Source Inc yet.
Cell Source Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Cell Source Inc
Cell Source, Inc., a biotechnology company, engages in developing cell therapy treatments based on the management of immune tolerance. Its lead product is the Veto Cell immune system management technology, which is an immune tolerance biotechnology that enables the selective blocking of immune responses. The company's Veto Cell technology is used in various applications, including treatment of lymphoma, leukemia, and multiple myeloma through facilitation of the stem cell tra…
Full company profileCell Source Inc financial statements
Cell Source Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Gross Profit | 0.00 | 0.00 | -407.00 | - | - | - | - | - | - | - |
| Operating Income | -2.32M | -2.29M | -2.01M | -3.81M | -3.64M | -4.02M | -4.18M | -4.18M | -3.85M | -2.73M |
| EBITDA | -3.56M | -2.86M | -2.01M | -460K | -3.64M | -93.4K | -4.18M | -4.18M | -3.60M | -2.73M |
| Net Income | -968K | -3.08M | -2.12M | -4.48M | -5.50M | -5.47M | -5.17M | -5.17M | -4.77M | -4.64M |
| EPS | -0.04 | -0.12 | -0.08 | -0.16 | -0.19 | -0.17 | -0.15 | -0.14 | -0.11 | -0.09 |
| Balance Sheet | ||||||||||
| Total Assets | 211K | 532K | 65.8K | 115K | 452K | 314K | 410K | 195K | 287K | 464K |
| Total Liabilities | 6.45M | 5.09M | 4.99M | 5.86M | 8.40M | 10.1M | 13.0M | 15.8M | 19.1M | 22.9M |
| Shareholders' Equity | -6.24M | -4.56M | -4.92M | -5.74M | -7.95M | -9.83M | -12.6M | -15.6M | -18.8M | -22.5M |
| Cash & Short-term Investments | 3.74K | 371K | 18.9K | 27.9K | 245K | 93.1K | 223K | 22.2K | 74.6K | 462K |
| Total Debt | 3.09M | - | 2.67M | 2.60M | 4.81M | 6.47M | - | 9.25M | 10.1M | 13.0M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -1.49M | -2.29M | -2.00M | -2.59M | -2.77M | -3.38M | -3.14M | -2.35M | -2.68M | -2.73M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.00 | 0.00 | 4.00 |
| Free Cash Flow | -1.49M | -2.29M | -2.00M | -2.59M | -2.77M | -3.38M | -3.14M | -2.35M | -2.68M | -2.73M |
| Ratios | ||||||||||
| ROA | -458.5% | -579.8% | -3,217.7% | -3,898.7% | -1,215.4% | -1,744.0% | -1,260.9% | -2,647.8% | -1,665.3% | -999.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROA
- Return on assets: net income divided by total assets.
Cell Source Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | USD 1.23T | 32,517 | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | USD 878B | 30,164 | - |
| 2019 | USD 742B | 26,192 | - |
| 2018 | USD 451B | 16,381 | - |
| 2017 | - | - | - |
| 2016 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Cell Source Inc
- Insiders 19.69%
- Institutions 0.00%
- Public & others 80.31%
- Shares outstanding 67.9M
- Free float 58.8M
Cell Source Inc company profile
- Company name
- Cell Source Inc
- Ticker
- CLCS.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1
- Fiscal year end
- December
- Address
- 57 West 57th Street, New York, NY, United States, 10019
- Phone
- 646 416 7896
- Website
- cell-source.com
About Cell Source Inc
Cell Source, Inc., a biotechnology company, engages in developing cell therapy treatments based on the management of immune tolerance. Its lead product is the Veto Cell immune system management technology, which is an immune tolerance biotechnology that enables the selective blocking of immune responses. The company's Veto Cell technology is used in various applications, including treatment of lymphoma, leukemia, and multiple myeloma through facilitation of the stem cell transplantation acceptance, as well as treatment of end stage kidney disease; other non-malignant organ diseases through organ transplantation; and various cancers and non-malignant diseases. Cell Source, Inc. was founded in 2012 and is headquartered in New York, New York.
Cell Source Inc management
2- Dr. Dennis M. Brown B.Sc., M.A., Ph.D.Executive Chairman · born 1950
- Mr. Itamar ShimratCEO, President & CFO · born 1959